卵巢癌组织学特异性自然史模型的开发与验证
本研究开发并验证了七种上皮性卵巢癌组织学亚型的自然史模型,模型为包含13个健康状态的状态转移模型,经校准后能复现SEER数据及两项大型筛查试验对照组的发病率和死亡率,模拟显示临床前阶段平均持续1至3年。
要点
- 研究建立了七种组织学亚型的卵巢癌自然史状态转移模型,经SEER数据校准。
- 模型在PLCO和UKCTOCS试验对照组中复现了观察到的发病率、死亡率和分期分布。
- 模拟显示临床前阶段平均持续1至3年,部分解释了筛查未能降低死亡率的原因。
核心结论
- 所开发的自然史模型准确描述了卵巢癌的组织学特异性自然进展,并为疾病自然史提供了重要见解。
- 模型可用于评估未来和新兴卵巢癌干预措施的影响,从而为决策者和政策制定者提供有价值的信息。
研究设计与样本
- 为上皮性卵巢癌最常见的组织学亚型(高级别浆液性癌、低级别浆液性癌、黏液性癌、透明细胞癌、子宫内膜样癌、癌肉瘤及非特指型)开发自然史模型。
- 每个模型模拟卵巢癌从发病至任何原因死亡的天然进展,采用包含13个互斥且穷尽健康状态的状态转移模型。
- 模型输入参数尽可能采用观察到的全国代表性估计值,未观察参数(如临床前转移)通过校准至SEER登记的组织学特异性数据来估计。
- 在PLCO和UKCTOCS试验的对照组中,就卵巢癌发病率和死亡率及诊断时分期分布对自然史模型进行验证。
主要发现
- 校准后的自然史模型复现了观察到的SEER数据(各组织学亚型加权均方根误差范围:0.0081-0.0185)以及各项校准目标:诊断后生存、诊断时分期分布和诊断时年龄分布(各组织学亚型均方误差范围分别为0.0029-0.0204、0.0005-0.0203和0.0637-0.0816)。
- 自然史模型复现了PLCO试验观察到的发病率和死亡率及诊断时分期(发病率P值=.411,死亡率P值=.195,诊断时分期分布P值=.200)。
- 自然史模型复现了UKCTOCS试验观察到的卵巢癌发病率(P值=.607)和死亡率(P值=.624)。
- 临床前阶段的平均持续时间在1至3年之间,部分解释了筛查未能产生死亡率下降的原因。
- 此外,II期卵巢癌独立于组织学亚型,是一个短暂状态,其平均持续时间明显短于I、III和IV期。
临床怎么用
- 作者认为,所开发的模型可用于评估未来和新兴卵巢癌干预措施的影响,从而为决策者和政策制定者提供有价值的信息。
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ovarian cancer is the second leading cause of death from gynecologic cancers, yet no effective screening program exists for the general population. Past screening trials evaluated the effectiveness of annual ovarian cancer screening and concluded that it does not yield substantial mortality reduction. Future investments on ovarian cancer screening trials would require convincing preliminary evidence on the effectiveness of interventions of interest. Simulation modeling is an effective, fast, cost-efficient, and safe approach to gain insights on the effectiveness of interventions, that is increasingly being used to inform guidelines for cancer screening programs. Models that simulate the natural progression of diseases in the absence of any intervention, commonly referred to as natural history models, are the cornerstone of such analyses, because they provide a reference point for evaluating interventions. Currently, no histology-specific natural history model exists for ovarian cancer despite major differences among subtypes. OBJECTIVE: Develop and validate a histology-specific ovarian cancer natural history model. STUDY DESIGN: We developed natural history models for the most common histological subtypes of epithelial ovarian cancer: high-grade serous carcinoma, low-grade serous carcinoma, mucinous carcinoma, clear cell carcinoma, endometrioid carcinoma, carcinosarcoma, and not otherwise specified. Each natural history model simulates the natural progression of ovarian cancer from disease's onset until death from any cause. We modeled ovarian cancer progression as a state-transition model comprising of 13 mutually exclusive and collectively exhaustive health states. We informed the model input parameters using observed, nationally representative estimates, whenever possible. Unobserved parameters (eg, preclinical transitions) were estimated through calibration to histology-specific data from the Surveillance, Epidemiology, and End Results registry. We validated the natural history models on the control arms of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial and the United Kingdom Collaborative Trial of Ovarian Cancer Screening trials, in terms of ovarian cancer incidence and mortality rates, and stage distribution at diagnosis. Differences between observed and estimated outcomes were assessed using traditional statistical tests. RESULTS: The calibrated natural history models reproduced the observed Surveillance, Epidemiology, and End Results data (range of weighted root mean square error across histological subtypes: 0.0081-0.0185) as well as individual calibration targets; survival after diagnosis, stage distribution at diagnosis, and age distribution at diagnosis (ranges of mean square error across histological subtypes: 0.0029-0.0204, 0.0005-0.0203, and 0.0637-0.0816, respectively). The natural history models reproduced the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial's observed incidence and mortality rates, and stage at diagnosis (P value=.411 for incidence, P value=.195 for mortality, and P value=.200 for stage distribution at diagnosis) and the United Kingdom Collaborative Trial of Ovarian Cancer Screening's observed ovarian cancer incidence (P value=.607) and mortality (P value=.624) rates. The average duration of the preclinical phase ranges between 1 and 3 years, which partly explains screening's failure to yield mortality reduction. Moreover, stage II ovarian cancer, independent of histological subtype, is a transient state characterized by noticeably shorter average duration when compared to stages I, III, and IV. CONCLUSION: The developed natural history models accurately describe the histology-specific natural progression of ovarian cancer and provide important insights into the natural history of the disease. The models may be used to evaluate the impact of future and emerging ovarian cancer interventions, thus providing valuable information to decision-makers and policymakers.
引用
- Ishizawa S, Eghbalizarch M, Nargund RS, et al. Development and validation of a histology-specific natural history model of ovarian cancer. Am J Obstet Gynecol. 2025. PMID: 40618976. doi:10.1016/j.ajog.2025.06.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。